Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane and coiled-coil domain family 2 (TMCC2) is a protein coded by the TMCC2 gene and localized to the endoplasmic reticulum membrane[6][7]. It contains coiled-coil and transmembrane domains, enabling oligomerization and intracellular protein interactions, and is conserved across species. TMCC2 is implicated in the metabolic process of amyloid precursor protein (APP), potentially influencing APP cleavage and the production of amyloid-β in Alzheimer's disease[2][3][6][7]. Its dysfunction in model organisms causes neurodevelopmental defects and features resembling early-onset Alzheimer’s pathology, including neurodegeneration, synaptic pathology, and accumulation of abnormal APP metabolites[2][3]. TMCC2 is not considered a classic therapeutic target, such as a receptor or enzyme, but is notable for its protein–protein interactions, role in ER homeostasis, and association with neurodegenerative disease[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane and coiled-coil domain family 2 (TMCC2).